Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer?
- PMID: 22439929
- DOI: 10.1016/j.ccr.2012.03.002
Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer?
Abstract
Pancreatic ductal adenocarcinoma (PDA) responds poorly to chemotherapy. In this issue of Cancer Cell, Provenzano et al. identify hyaluronan as a pivotal determinant of elevated interstitial fluid pressures (IFP) and vascular collapse in PDA. PEGPH20 treatment ablates stromal hyaluronan, normalizes IFP, and increases accessibility of tumor cells to anticancer drugs.
Copyright © 2012 Elsevier Inc. All rights reserved.
Comment on
-
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.Cancer Cell. 2012 Mar 20;21(3):418-29. doi: 10.1016/j.ccr.2012.01.007. Cancer Cell. 2012. PMID: 22439937 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Molecular Biology Databases